Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Mar 2, 2023 · 10-K · 61 days after period end · 0000950170-23-005705
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $168.00K | $3.64M | — | $0.00 |
| Net Income | -$18.82M | -$20.45M | -$22.71M | -$21.50M |
| EPS Diluted | — | — | -$0.35 | -$0.65 |
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 2, 2023 · 61 d after period end
